VX 803

Drug Profile

VX 803

Alternative Names: VX-803

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 11 Jan 2017 VX 803 licensed to Merck worldwide
  • 10 Mar 2015 Vertex Pharmaceuticals has patent protection for VX 803 in USA (Vertex 10-K, March 2015)
  • 01 Jan 2015 Phase-I clinical trials in Lymphoma (Late-stage disease, Second-line therapy or greater) in United Kingdom, Netherlands (unspecified route) after January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top